Ashwini Esnakula

Dr. Ashwini Esnakula

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
DYDennis Yang
Dennis Yang
ATArvind J. Trindade
Arvind J. Trindade
PYPatrick Yachimski
Patrick Yachimski
PBPetros Benias
Petros Benias
JNJose Nieto
Jose Nieto
PDPeter V. Draganov
Peter V. Draganov

26 November 2014
Verified
Journal Article
Closed access
YKYasmine M Kanaan
Yasmine M Kanaan
BSBrante P Sampey
Brante P Sampey
DBDesta Beyene
Desta Beyene
AEAshwini Esnakula
Ashwini Esnakula
TNTammey J Naab
Tammey J Naab
RDRobert L DeWitty
Robert L DeWitty

19 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAshish Manne
Ashish Manne
AEAshwini Esnakula
Ashwini Esnakula
LALaith Abushahin
Laith Abushahin
ATAllan Tsung
Allan Tsung
Mucin-5AC (MUC5AC) is a heavily glycosylated gel-forming secreted mucin with a reliable prognostic value when detected in multiple malignancies. It is highly prevalent (70%) in PDA and is nonexistent in normal pancreatic tissues. Retrospective studies on PDA tumor tissue (detected by immunohistochemistry or IHC)) have investigated the prognostic value of MUC5AC expression but were equivocal. Some studies associated it with poor outcomes (survival or pathological features such as lymph node disease, vascular/neural invasion in resected tumors), while others have concluded that it is a good prognostic marker. The examination of expression level threshold (5%, 10%, or 25%) and the detected region (apical vs. cytoplasmic) were variable among the studies. The maturation stage and glycoform of MUC5AC detected also differed with the Monoclonal antibody (Mab) employed for IHC. CLH2 detects less mature/less glycosylated versions while 45M1 or 21-1 detect mature/more glycosylated forms. Interestingly, aberrantly glycosylated variants of MUC5AC were detected using lectin assays (Wheat Germ Agglutinin-MUC5AC), and Mabs such as NPC-1C and PAM4 have are more specific to malignant pancreatic tissues. NPC-1C and PAM4 antibody reactive epitopes on MUC5AC are immunogenic and could represent specific changes on the native MUC5AC glycoprotein linked to carcinogenesis. It was never studied to predict treatment response.

13 May 2013 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
AEAshwini Esnakula
Ashwini Esnakula
ISIrorere Summers
Irorere Summers
TNTammey J. Naab
Tammey J. Naab
Systemic mycotic infections have been increasing in incidence in immunocompromised patients. Although yeasts are most often isolated, opportunistic fungal infections may also be caused by filamentous fungi, includingAspergillusandFusarium. LikeAspergillus,Fusariumis angioinvasive with an ability to disseminate widely. Disseminated fusariosis is most commonly linked to prolonged neutropenia. Disseminated infections due toFusariumare rare in Human Immunodeficiency Virus (HIV) positive patients but have been reported in HIV positive patients with neutropenia and lymphoma. We describe an HIV positive patient without neutropenia, skin lesions, or concomitant malignancy, who developed fatal disseminated infection with possible endocarditis due toFusarium solani. Early identification ofFusariumis important because of its high level of resistance to several antifungal drugs, with response often requiring combination therapy.

14 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
QJQi Jin
Qi Jin
NSNi Shi
Ni Shi
DLDong Hoon Lee
Dong Hoon Lee
KRKathryn M. Rexrode
Kathryn M. Rexrode
JMJoAnn E. Manson
JoAnn E. Manson
FTFred Tabung
Fred Tabung
We evaluated associations of the Empirical Dietary Index for Hyperinsulinemia (EDIH), Empirical Dietary Inflammatory Pattern (EDIP) and Healthy Eating Index (HEI2015) and their metabolomics profiles with the risk of total and site-specific cancers. We used baseline food frequency questionnaires to calculate dietary scores among 112,468 postmenopausal women in the Women’s Health Initiative. We used multivariable-adjusted Cox regression to estimate hazard ratios (HR) and 95% confidence intervals for cancer risk estimation. Metabolomic profile scores were derived using elastic-net regression with leave-one-out cross validation. In over 17.8 years, 18,768 incident invasive cancers were adjudicated. Higher EDIH and EDIP scores were associated with greater total cancer risk, and higher HEI-2015 with lower risk: HRQ5vsQ1(95% CI): EDIH, 1.10 (1.04–1.15); EDIP, 1.08 (1.02–1.15); HEI-2015, 0.93 (0.89–0.98). The multivariable-adjusted incidence rate difference(Q5vsQ1) for total cancer was: +52 (EDIH), +41 (EDIP) and −49 (HEI-2015) per 100,000 person years. All three indices were associated with colorectal cancer, and EDIH and EDIP with endometrial and breast cancer risk. EDIH was further associated with luminal-B, ER-negative and triple negative breast cancer subtypes. Dietary patterns contributing to hyperinsulinemia and inflammation were associated with greater cancer risk, and higher overall dietary quality, with lower risk. The findings warrant the testing of these dietary patterns in clinical trials for cancer prevention among postmenopausal women.

Verified
Journal Article
Open access
PDF file
AMAshish Manne
Ashish Manne
AKAnup Kasi
Anup Kasi
AEAshwini Esnakula
Ashwini Esnakula
RPRavi Paluri
Ravi Paluri
Mucin 5AC (MUC5AC) glycoprotein plays a crucial role in carcinogenesis and drug sensitivity in pancreatic ductal adenocarcinoma (PDAC), both individually and in combination with other mucins. Its function and localization are glycoform-specific. The immature isoform (detected by the CLH2 monoclonal antibody, or mab) is usually in the perinuclear (cytoplasmic) region, while the mature (45 M1, 2-11, Nd2) variants are in apical and extracellular regions. There is preclinical evidence suggesting that mature MUC5AC has prognostic and predictive (response to treatment) value. However, these findings were not validated in clinical studies. We propose a MUC5AC signature with three components of MUC5AC—localization, variant composition, and intensity—suggesting a reliable marker in combination of variants than with individual MUC5AC variants alone. We also postulate a theory to explain the occurrence of different MUC5AC variants in abnormal pancreatic lesions (benign, precancerous, and cancerous). We also analyzed the effect of mature MUC5AC on sensitivity to drugs often used in PDAC management, such as gemcitabine, 5-fluorouracil, oxaliplatin, irinotecan, cisplatin, and paclitaxel. We found preliminary evidence of its predictive value, but there is a need for large-scale studies to validate them.